Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment
https://pixabay.com/en/hand-world-ball-keep-child-earth-644145/

Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment

Galecto has announced they have completed enrollment in their Phase2b trial which will investigate GB0139 as a treatment for idiopathic pulmonary fibrosis (IPF). This trial is called GALACTIC-1. Galecto anticipates…

Continue Reading Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment
Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment
jarmoluk / Pixabay

Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment

Aeterna Zentaris’s ongoing DETECT trial is evaluating the drug macimorelin (tradename Macrilen™) for childhood-onset growth hormone deficiency (CGHD). As recently announced in an article published by GlobeNewsWire, the study (AEZS-130-PO2),…

Continue Reading Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment

A New Standard for Corticosteroid Dosing for Childhood-Onset SLE with Proliferative Lupus Nephritis

Recently, an international group of pediatric rheumatologists and nephrologists met and created a consensus on a standard for a steroid-dosing regimen to treat childhood-onset systemic lupus erythematosus with proliferative lupus…

Continue Reading A New Standard for Corticosteroid Dosing for Childhood-Onset SLE with Proliferative Lupus Nephritis